Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 4;9:9687. doi: 10.1038/s41598-019-41053-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

MiR-103/107-Axin2 axis correlates with poor prognosis of CRC patients. (A) Representing ISH staining for miR-103/107 expression and IHC staining for Axin2 expression in two CRC patient specimens. Bar, 50 mm. (B) Inverse correlation of miR-103/107 expression and Axin2 expression in CRC specimens. Pearson correlation test was used for comparison between groups. (C) Kaplan–Meier analysis of overall survival and disease-free survival of CRC patients with the corresponding expression profiles. Log-Rank test was used for comparison between groups. (D) Comparison of miR-103/107 level by response of patients to oxaliplatin treatment. Response group includes complete or partial response, while non-response one includes stable or progressive disease. Data are mean ± S.D.